In August 2025, AbbVie organized a study is to assess adverse events and change in disease activity when Telisotuzumab ...

Investigators have developed a prognostic model that may identify which patients with MIBC are suitable for bladder-preserving chemoradiation.

Artificial neural networks predicted overall and progression-free survival after chemoradiation in older adults with head and ...

Stage 2 cervical cancer is classified into 2A and 2B, based on tumor spread and size, affecting treatment decisions.

Regeneron Canada Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by public drug programs in Ontario, British Columbia, Saskatchewan, Nova Scotia, Newfoundland and ...

Regeneron Canada Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by Régie de l'assurance maladie du Québec (RAMQ) in Québec for adults with advanced non-small cell ...

Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a significant clinical ...

Akeso, Inc. (($HK:9926)) announced an update on their ongoing clinical study. Akeso, Inc. has announced a new clinical study titled ‘A ...

Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas ASCO Guidelines ...

About Safusidenib Safusidenib is a novel, oral, potent, brain-penetrant, targeted inhibitor of mutant IDH1. In a Phase 1 clinical study, safusidenib was well-tolerated and demonstrated anti-tumor ...

Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio 43210, United States ...